Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT02499328	TitleStudy to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck	Fase Phase 1, Phase 2	Date Added 2015-07-16	Ubicación Alabama, United States California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Bélgica Alemania Italia España Reino Unido	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas AZD5069, AZD9150, MEDI4736, tremelimumab (treme)	Etiquetas MSS/ MMRp
NCT ID NCT06107413	TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	Fase Fase 2	Date Added 2023-10-30	Ubicación Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Bélgica Alemania Israel Japón Corea, República de España Taiwán	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan	Etiquetas MSS/ MMRp
NCT ID NCT05425940	TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)	Fase Fase 3	Date Added 2022-06-21	Ubicación Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Bélgica Francia Alemania Hong Kong Hungary Corea, República de Nueva Zelanda Polonia Portugal Singapur España Taiwán Tailandia Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq	Etiquetas MSS/ MMRp
NCT ID NCT05784688	TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Fase Phase 1, Phase 2	Date Added 2023-03-27	Ubicación Texas, United States Washington, United States Corea, República de	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas TU2218 + Pembrolizumab	Etiquetas MSS/ MMRp
NCT ID NCT03835949	TitleStudy of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer	Fase Fase 1	Date Added 2019-02-11	Ubicación Alabama, United States Arizona, United States California, United States Texas, United States	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas Atezolizumab, TJ004309	Etiquetas MSS/ MMRp
NCT ID NCT05350917	TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy	Fase Fase 2	Date Added 2022-04-28	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas Tislelizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03865082	TitleStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)	Fase Fase 2	Date Added 2019-03-06	Ubicación Arizona, United States California, United States Texas, United States	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy	Etiquetas MSS/ MMRp
NCT ID NCT02869217	TitleStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors	Fase Fase 1	Date Added 2016-08-16	Ubicación Canadá	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Cyclophosphamide, Fludarabine, TBI-1301	Etiquetas MSS/ MMRp
NCT ID NCT03223779	TitleEstudio de TAS-102 más radioterapia para el tratamiento del hígado en pacientes con metástasis hepáticas de cáncer colorrectal	Fase Fase 1	Date Added 2017-07-21	Ubicación Massachusetts, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03711058	TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer	Fase Phase 1, Phase 2	Date Added 2018-10-18	Ubicación Maryland, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Copanlisib, Nivolumab	Etiquetas MSS/ MMRp

Showing 31 to 40 of 299 entries